PI
TARA icon

Pharmstandard International’s Protara Therapeutics TARA Stock Holding History

Pharmstandard International’s Portfolio TARA Stock Details TARA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q3 		$3.13M Hold
40,195
– – 10.79% 5
2018
Q2 		$3.94M Sell
40,195
-1,503
-4% -$140K 15.8% 4
2018
Q1 		$4.17M Hold
41,698
– – 10.47% 4
2017
Q4 		$3.17K Hold
41,698
– – 3.26% 6
2017
Q3 		$3.34M Buy
41,698
+12,564
+43% +$719K 9.72% 3
2017
Q2 		$1.78M Hold
29,134
– – 6.16% 5
2017
Q1 		$2.04M Hold
29,134
– – 5.44% 5
2016
Q4 		$2.21M Buy
+29,134
New +$9.21M 1.91% 4

Other funds holding TARA

A
Abingworth London, United Kingdom $307M AUM 93.47% 1-Year Est. Return
NLVP
New Leaf Venture Partners New York $43M AUM 25.55% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return
MAM
MPM Asset Management Boston, Massachusetts $44.5M AUM 47.28% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
DVC
Deer VII & Co Larchmont, New York $317M AUM 30.89% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Pharmstandard International's TARA Position: Q3 2018 in Review

Pharmstandard International held its Protara Therapeutics (TARA) position steady in Q3 2018 at 40,195 shares worth $3.13M. The position accounts for 10.79% of the portfolio, ranked #5.

Pharmstandard International first reported a position in TARA in Q4 2016 and has held it in 8 quarters since. The position peaked at $4.17M in Q1 2018. 27 funds tracked by Wall St. Rank hold TARA as of Q3 2018.

  • Pharmstandard International held 40,195 shares of Protara Therapeutics worth $3.13M as of Q3 2018.
  • Pharmstandard International left its Protara Therapeutics share count unchanged in Q3 2018.
  • Protara Therapeutics made up 10.79% of Pharmstandard International's portfolio in Q3 2018, its #5 holding.
  • Pharmstandard International first reported a position in Protara Therapeutics in Q4 2016 and has held it in 8 quarters since.
  • Pharmstandard International's Protara Therapeutics position peaked at $4.17M in Q1 2018.
  • 27 funds tracked by Wall St. Rank held Protara Therapeutics as of Q3 2018.

Based on Pharmstandard International's 13F filing for Q3 2018, filed 15 Nov 2018.